Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ ) 0.4244 -0.0034 (-0.79%) Streaming Delayed Price Updated: 3:59 PM EDT, Jul 17, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 528,451 Open 0.4166 Bid (Size) 0.4238 (17) Ask (Size) 0.4300 (10) Prev. Close 0.4278 Today's Range 0.4011 - 0.4390 52wk Range 0.3150 - 4.790 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good July 10, 2024 This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday July 09, 2024 It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! Via InvestorPlace Performance YTD -63.73% -63.73% 1 Month -29.27% -29.27% 3 Month -54.42% -54.42% 6 Month -61.06% -61.06% 1 Year -90.69% -90.69% More News Read More Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket July 09, 2024 Via Benzinga Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test July 09, 2024 From Mainz BioMed NV Via GlobeNewswire Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session July 08, 2024 Via Benzinga mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment July 02, 2024 Via Benzinga Exposures COVID-19 Mainz Biomed Provides Half Year 2024 Corporate Update July 02, 2024 From Mainz BioMed NV Via GlobeNewswire Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight June 26, 2024 Via Benzinga Mainz Biomed’s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks June 21, 2024 Via News Direct Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate June 05, 2024 Via News Direct Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon June 04, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 04, 2024 Via Benzinga Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024 June 03, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Reports Results of 2024 Annual General Meeting May 31, 2024 From Mainz BioMed NV Via GlobeNewswire Why Ooma Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket May 29, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 29, 2024 Via InvestorPlace Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting May 28, 2024 From Mainz BioMed NV Via GlobeNewswire Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial May 20, 2024 From Mainz BioMed NV Via GlobeNewswire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday May 17, 2024 Via InvestorPlace Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game May 16, 2024 Via Benzinga Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. May 07, 2024 From Mainz BioMed NV Via GlobeNewswire mRNA Is Promising A Breakthrough In Fighting Cancer April 29, 2024 Via Benzinga Exposures COVID-19 Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic April 25, 2024 From Mainz BioMed NV Via GlobeNewswire The Pharmaceutical Industry Finds Itself At A Historical Crossroads April 10, 2024 Via Benzinga MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 April 09, 2024 Via InvestorPlace Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
